Why Azure Minerals, Global Lithium, Mesoblast, and Neuren shares are racing higher

These ASX shares are having a strong finish to the week.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a high. At the time of writing, the benchmark index is up 0.9% to 7,312.5 points.

Four ASX shares that are climbing more than most today are listed below. Here's why they are rising:

Five people in an office high five each other.

Image source: Getty Images

Azure Minerals Ltd (ASX: AZS)

The Azure Minerals share price is up over 3% to $1.67. Investors have been buying this lithium explorer's shares after it announced further promising assay results from the Andover Project. According to the release, the assays have confirmed two more "very broad intersections" of lithium mineralisation.

Global Lithium Resources Ltd (ASX: GL1)

The Global Lithium share price is up 5.5% to $1.74. This morning, analysts at Macquarie responded positively to news of a rare earths discovery at the Manna lithium project. This has seen the broker retain its outperform rating and $2.50 price target on the company's shares.

Mesoblast Ltd (ASX: MSB)

The Mesoblast share price is up 8% to $1.39. Investors have been buying this biotech company's shares recently amid optimism that a major regulatory approval is coming in the next couple of weeks. Bell Potter appears to believe good news could be on the way. As a result, earlier this week it retained its speculative buy rating with a $2 price target.

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren Pharmaceuticals share price is up 17% to $13.59. This has been driven by news that the company has expanded its partnership with Acadia Pharmaceuticals. The latter will now have an exclusive licence for trofinetide worldwide instead of just North America. Neuren will receive US$100 million up-front, plus additional potential milestone payments of up to US$427 million and royalties on net sales of trofinetide outside North America. Trofinetide is a treatment for Rett syndrome.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

An ASX investor relaxes on her couch as the Harvey Norman share price drops due to the shares trading ex-dividend from today.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to pull a rabbit out of the hat today.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough session for the ASX this Thursday.

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a volatile, but successful, day for investors.

Read more »

Three men stand on a winner's podium with medals around their necks and their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a muted day on the ASX.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy start to the trading week this Monday.

Read more »

Girl with painted hands.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a remarkably positive end to the trading week.

Read more »

3 children standing on podiums wearing Olympic medals.
Share Gainers

Here are the top 10 ASX 200 shares today

A late rally couldn't save the ASX this Thursday.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rather woeful Wednesday for the markets.

Read more »